.Pharmacolibrary.Drugs.ATC.S.S01AA18

Information

Polymyxin B is an antibiotic primarily used to treat severe Gram-negative bacterial infections, including those caused by multidrug-resistant bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. It is typically administered intravenously or topically and is reserved for serious infections due to potential nephrotoxicity and neurotoxicity. Polymyxin B is approved and used in clinical practice, especially for life-threatening infections where alternative treatments are not effective.

Pharmacokinetics

Pharmacokinetic parameters reported for adult critically ill patients treated with IV polymyxin B, based on population pharmacokinetic analysis.

References

1. Kubin, CJ, et al., & Yin, MT (2018). Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. Antimicrobial agents and chemotherapy 62(3) –. DOI:10.1128/AAC.01493-17 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29311066

2. Hanafin, PO, et al., & Rao, GG (2023). A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 29(9) 1174–1181. DOI:10.1016/j.cmi.2023.05.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37217076

3. Wang, PL, et al., & Yang, J (2022). Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections. The Journal of antimicrobial chemotherapy 77(11) 3000–3008. DOI:10.1093/jac/dkac265 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35924405

Revisions

• 06/2025 initial generated model